Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03102606 · ClinicalTrials.gov registry record · Phase 3
Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3
A Phase 3 study, sponsored by BeyondSpring Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 105
- Enrollment target
NCT03102606 is a Phase 3 study that has completed, run by BeyondSpring Pharmaceuticals. The registered enrollment target is 105 participants.
The verdict
NCT03102606, a Phase 3 study, has completed, sponsored by BeyondSpring Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 105 participants
- Enrollment target
Study Summary
To assess Duration of Severe Neutropenia (DSN) in treatment Cycle 1 in patients with advanced or metastatic breast cancer, who have failed \>/= 1 but \< 5 prior lines of chemotherapy; locally advanced or metastatic non small cell lung cancer (NSCLC) after platinum therapy failure; or hormone refractory (androgen independent) metastatic prostate cancer treated with docetaxel (75 mg/m2) + plinabulin (40 mg) versus docetaxel (75 mg/m2) + pegfilgrastim (6 mg). Neutrophils count will be assessed at baseline; Pre dose during Cycle 1, Day 1, 2, 6, 7, 8, 9, 10, 15. \*Study is officially closed on 08 Feb 2021\*
Interventions
- OTHER Saline Placebo
- DRUG Pegfilgrastim
- DRUG Plinabulin
- OTHER D5W Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2018-05-29 |
| Est. Completion | 2021-02-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03102606
The ClinicalTrials.gov registry entry for NCT03102606 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BeyondSpring Pharmaceuticals, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Saline Placebo is the first listed.
NCT03102606 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03102606 about?
NCT03102606 is a clinical study titled "Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3". To assess Duration of Severe Neutropenia (DSN) in treatment Cycle 1 in patients with advanced or metastatic breast cancer, who have failed \>/= 1 but \< 5 prior lines of chemotherapy; locally advanced or metastatic non small cell lung cancer (NSCLC) after platinum therapy failure; or hormone refract...
What is the current status of trial NCT03102606?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 105 participants. The study started on 2018-05-29. Estimated completion is 2021-02-08.
What interventions are being tested in trial NCT03102606?
The interventions under investigation include: Saline Placebo (OTHER), Pegfilgrastim (DRUG), Plinabulin (DRUG), D5W Placebo (OTHER).
Who is sponsoring clinical trial NCT03102606?
This trial is sponsored by BeyondSpring Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.